摘要
目的探讨血清白细胞介素37(IL-37)在慢性乙型肝炎(CHB)、乙型慢加急性肝衰竭(ACHBLF)和乙型肝炎后肝硬化(PHBC)中的意义。方法分别选取2015年10月至2016年10月中山大学附属第三医院门诊和住院部就诊的CHB患者49例、ACHBLF患者20例和PHBC患者18例,健康对照组34例为本院健康志愿者,检测各组血清中谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBil)、HBV-DNA、IL-37、TNFα的水平。结果 CHB、ACHBLF和PHBC组患者中,血清IL-37的表达水平明显高于对对照组,且HBe Ag阳性患者血清IL-37较HBe Ag阴性患者明显升高,差异均有统计学意义(P均<0.05)。HBV感染者中,HBV DNA阳性患者血清IL-37明显高于HBV DNA阴性患者,差异有统计学意义(P<0.05)。CHB和ACHBLF组患者血清IL-37与ALT、AST、HBV DNA呈正相关(R=0.608 4,R=0.574 4,R=0.649 2,P均<0.05;R=0.636 8,R=0.678 2,R=0.978 5,P均<0.05);CHB、ACHBLF和PHBC患者血清IL-37与TBil、TNFα无相关性(P>0.05)。结论 CHB、ACHBLF和PHBC患者血清IL-37的表达可能与HBV DNA水平和HBe Ag血清学转换有关,并能够反映CHB、PHBC患者肝脏炎症程度。IL-37可作为乙型肝炎治疗的一个新指标。
Objective To explore the clinical significance of serum interleukine-37（IL-37）levels in patients with chronic hepatitis B（CHB）,acute-on-chronic HBV-related liver failure（ACHBLF）,and post-hepatitis B liver cirrhosis（PHBC）.Methods 49 patients with CHB,20 patients with ACHBLF and 18 patients with PHBC were collected in this study,and34 healthy people were selected as healthy control（HC）. The expression levels of IL-37 and tumor necrosis factor α（TNFα）were detected by enzyme linked immunosorbent assay. Results In CHB,ACHBLF and PHBC groups,the serum levels of IL-37 were significantly higher than HC at baseline（all P〈0.05）,and the serum levels of IL-37 in HBeAg-positive patients were significantly higher than that of HBeAg-negative patients（all P〈0.05）. Compared to HBV DNA-negative patients,serum IL-37 level of HBV DNA-positive patients was significantly increased in HBV-infected patients（P〈0.05）.The levels of IL-37 were positively correlated with ALT,AST and HBV DNA（R=0.608 4,R=0.574 4,R=0.649 2,respectively,all P〈0.05;R=0.636 8,R=0.678 2,R=0.978 5,respectively,all P〈0.05）in CHB and ACHBLF groups. The levels of IL-37 had no statistical correlation with TBil and TNFα（all P〉0.05）in CHB,ACHBLF and PHBC groups.Conclusions IL-37 may play a critical role in the change of HBV DNA or HBeAg seroconversion in CHB,ACHBLF and PHBC groups,and can reflect the degree of liver inflammation in CHB,PHBC groups. In future,IL-37 may be the therapeutic target to HBV infection.
出处
《热带医学杂志》
CAS
2017年第4期442-446,共5页
Journal of Tropical Medicine
基金
广东省科技计划项目(2010B060900041)
